McKesson Toekomstige groei
Future criteriumcontroles 2/6
McKesson zal naar verwachting groeien in winst en omzet met respectievelijk 15% en 8.1% per jaar. De winst per aandeel zal naar verwachting groeien met 19% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 568.1% zijn.
Belangrijke informatie
15.0%
Groei van de winst
19.0%
Groei van de winst per aandeel
| Healthcare winstgroei | 20.8% |
| Inkomstengroei | 8.1% |
| Toekomstig rendement op eigen vermogen | 568.1% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 19 Nov 2024 |
Recente toekomstige groei-updates
Recent updates
McKesson's (NYSE:MCK) Soft Earnings Don't Show The Whole Picture
Nov 14
McKesson: Q2 FY2025 Earnings, Growing U.S. Oncology Network
Nov 09McKesson Corporation: A Defensive Healthcare Value Stock Without A Patent Cliff
Oct 09McKesson: The Correction Is Not Over
Sep 10McKesson Corporation (NYSE:MCK) Not Lagging Market On Growth Or Pricing
Aug 22McKesson Corporation: An Interesting Health Giant With A Hidden Gem
Jul 04With McKesson Corporation (NYSE:MCK) It Looks Like You'll Get What You Pay For
May 09Is McKesson Corporation (NYSE:MCK) Trading At A 43% Discount?
Mar 14McKesson: GLP-1 Contributed More Than 1/3 Of Growth
Feb 19McKesson's (NYSE:MCK) Profits May Not Reveal Underlying Issues
Feb 16Investor Optimism Abounds McKesson Corporation (NYSE:MCK) But Growth Is Lacking
Jan 29McKesson: Why The Company Is Too Richly Valued
Jan 19If EPS Growth Is Important To You, McKesson (NYSE:MCK) Presents An Opportunity
Nov 20McKesson: GLP-1 Medications Tailwinds And Massive Share Repurchase
Nov 08Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 44%?
Oct 30McKesson: Still Trading For A Huge Discount
Sep 06Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
Aug 21Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 29%?
Jul 27McKesson: Outlook Remains Positive, I Reiterate My Buy Recommendation
Jun 28Here's Why McKesson (NYSE:MCK) Has Caught The Eye Of Investors
May 23Are Investors Undervaluing McKesson Corporation (NYSE:MCK) By 32%?
Apr 17Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?
Feb 22McKesson Corporation: Looking Forward To Long-Term Low-Teens EPS Growth
Feb 08McKesson Non-GAAP EPS of $6.90 beats by $0.54, revenue of $70.5B misses by $480M
Feb 01McKesson Corporation's (NYSE:MCK) Intrinsic Value Is Potentially 33% Above Its Share Price
Jan 125 Reasons Why I Am Considering Adding McKesson To My Portfolio
Dec 27McKesson Corporation: Still Trading Below Intrinsic Value
Dec 13Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 3/31/2027 | 418,942 | 4,295 | 5,758 | 6,512 | 11 |
| 3/31/2026 | 391,883 | 3,952 | 5,006 | 6,064 | 15 |
| 3/31/2025 | 359,959 | 3,097 | 5,051 | 5,857 | 13 |
| 9/30/2024 | 330,187 | 2,536 | 4,313 | 5,121 | N/A |
| 6/30/2024 | 313,751 | 2,959 | 3,256 | 3,986 | N/A |
| 3/31/2024 | 308,951 | 3,002 | 3,627 | 4,314 | N/A |
| 12/31/2023 | 301,506 | 2,998 | 2,892 | 3,492 | N/A |
| 9/30/2023 | 291,098 | 3,487 | 4,306 | 4,906 | N/A |
| 6/30/2023 | 284,040 | 3,755 | 4,466 | 5,048 | N/A |
| 3/31/2023 | 276,711 | 3,563 | 4,601 | 5,159 | N/A |
| 12/31/2022 | 273,903 | 3,146 | 4,190 | 4,721 | N/A |
| 9/30/2022 | 272,027 | 2,061 | 3,952 | 4,430 | N/A |
| 6/30/2022 | 268,446 | 1,396 | 4,639 | 5,115 | N/A |
| 3/31/2022 | 263,966 | 1,119 | 3,899 | 4,434 | N/A |
| 12/31/2021 | 257,006 | 1,415 | 4,323 | 4,917 | N/A |
| 9/30/2021 | 250,991 | -4,804 | 4,098 | 4,753 | N/A |
| 6/30/2021 | 245,223 | -4,494 | 3,299 | 3,982 | N/A |
| 3/31/2021 | 238,228 | -4,538 | 3,901 | 4,542 | N/A |
| 12/31/2020 | 237,621 | -4,189 | 5,231 | 5,826 | N/A |
| 9/30/2020 | 234,194 | 2,228 | 3,905 | 4,492 | N/A |
| 6/30/2020 | 231,002 | 922 | 2,851 | 3,363 | N/A |
| 3/31/2020 | 231,051 | 906 | 3,868 | 4,374 | N/A |
| 12/31/2019 | 224,945 | -905 | 3,125 | 3,615 | N/A |
| 9/30/2019 | 221,981 | -626 | 3,066 | 3,559 | N/A |
| 6/30/2019 | 217,440 | 601 | 4,523 | 5,046 | N/A |
| 3/31/2019 | 214,319 | 33 | 3,479 | 4,036 | N/A |
| 12/31/2018 | 213,518 | -319 | 2,572 | 3,165 | N/A |
| 9/30/2018 | 210,927 | 113 | 2,751 | 3,324 | N/A |
| 6/30/2018 | 209,913 | -384 | N/A | 2,543 | N/A |
| 3/31/2018 | 208,357 | 62 | N/A | 4,345 | N/A |
| 12/31/2017 | 205,442 | 4,805 | N/A | 2,756 | N/A |
| 9/30/2017 | 201,955 | 4,539 | N/A | 3,155 | N/A |
| 6/30/2017 | 199,851 | 4,846 | N/A | 3,626 | N/A |
| 3/31/2017 | 198,533 | 5,194 | N/A | 4,744 | N/A |
| 12/31/2016 | 196,498 | 2,051 | N/A | 6,415 | N/A |
| 9/30/2016 | 194,267 | 2,044 | N/A | 5,349 | N/A |
| 6/30/2016 | 193,071 | 2,359 | N/A | 5,077 | N/A |
| 3/31/2016 | 190,884 | 2,290 | N/A | 3,672 | N/A |
| 12/31/2015 | 189,131 | 2,237 | N/A | 2,449 | N/A |
| 9/30/2015 | 187,716 | 2,090 | N/A | 4,198 | N/A |
| 6/30/2015 | 183,115 | 1,950 | N/A | 3,384 | N/A |
| 3/31/2015 | 179,045 | 1,775 | N/A | 3,112 | N/A |
| 12/31/2014 | 171,952 | 1,780 | N/A | 3,893 | N/A |
| 9/30/2014 | 159,804 | 1,462 | N/A | 2,488 | N/A |
| 6/30/2014 | 148,629 | 1,402 | N/A | 2,602 | N/A |
| 3/31/2014 | 137,392 | 1,419 | N/A | 3,136 | N/A |
| 12/31/2013 | 130,076 | 1,278 | N/A | 2,679 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei MCK ( 15% per jaar) ligt boven de spaarquote ( 2.6% ).
Winst versus markt: De winst van MCK ( 15% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 15.4% per jaar).
Hoge groeiwinsten: De winst van MCK zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van MCK ( 8.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 9% per jaar).
Hoge groei-inkomsten: De omzet van MCK ( 8.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen MCK zal naar verwachting over 3 jaar zeer hoog zijn ( 568.1 %).